NDA Partners Chairman Carl Peck, MD, announced today that Felix Frueh, PhD, who formerly served as the Associate Director for Genomics in the Center for Drug Evaluation and Research, where he led the FDA’s first genetic and genomic review division, has joined the firm as an Expert Consultant.
ROCHELLE, VA. (PRWEB) SEPTEMBER 04, 2019
NDA Partners Chairman Carl Peck, MD, announced today that Felix Frueh, PhD, a senior life sciences executive with expertise in corporate, regulatory, and commercialization strategies with a focus on precision medicine, who formerly served as the Associate Director for Genomics in the Center for Drug Evaluation and Research, has joined the firm as an Expert Consultant. In his role as Associate Director for Genomics, he led the FDA’s first genetic and genomic review division and established the biomarker qualification process and companion diagnostic development policies.
In addition to his FDA career, Dr. Frueh oversaw the creation and led the world’s largest next-generation, CLIA-certified, whole human genome sequencing laboratory as the Chief Scientific Officer of Human Longevity (HLI). Prior, he served as President of Medco Research Institute, Research Director for Pharmacogenetics of Transgenomic, and Assistant Director of Protogene Laboratories. He is Founder and Executive Partner of Opus Three, Co-founder and Partner of Profound Ventures, and Co-founder and Chief Scientific Officer of Selva Therapeutics. He also co-founded and formerly served as the Chief Executive Officer of Intellos Health.
“Dr. Frueh is a well-respected senior life sciences executive with expertise in corporate, regulatory, and commercialization strategies with a focus on precision medicine. We are pleased to welcome Dr. Frueh to NDA Partners, where his knowledge of genetic and genomic products will provide significant value to our clients developing precision medicine therapies,” said Dr. Peck.
Dr. Frueh received his PhD in biochemistry from the University of Basel in Switzerland and completed postdoctoral fellowships at the University of Basel and Stanford University. He has served as a consultant, strategic advisor, and board member to numerous diagnostic, pharmaceutical, and other health care companies. He is the author of more than 100 peer-reviewed articles, book chapters, white papers, market analyses, strategies, and business plans.
About NDA Partners
NDA Partners is a life sciences management consulting and contract development organization (CDO) focused on providing product development and regulatory services to the pharmaceutical, biotechnology, and medical device industries worldwide. The highly experienced Principals and Premier Experts of NDA Partners include three former FDA Center Directors; the former Chairman of the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK; the former Chief Executive Officer and Chief Science Officer at the United States Pharmacopeial Convention (USP); an international team of more than 100 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, medical device design control and quality systems, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, expert consulting, high-impact project teams, and contract management of client product development programs.
Contact
Earle Martin, Chief Executive Officer
Office: 540-738-2550
[email protected]
We are pleased to welcome Dr. Frueh to NDA Partners, where his knowledge of genetic and genomic products will provide significant value to our clients developing precision medicine therapies
